SBIR/STTR programs will expire if Congress doesn’t reauthorize by September 30th. Senator Paul blocked reauthorization because of security problems. New provisions added to address security concerns.
Bill passed Senate, expected to pass House. SBIR/STTR programs extended for three more years.
Tag Archive for: NCI
SBIR/STTR programs could expire Sept 30. Reauthorization opposed by Rand Paul and others. SBIR/STTR grants enable commercialization of federally funded research and have broad benefits that improve life for all Americans as well as billions around the globe.
NCI and CDMRP are awarding over $7 BILLION in funding for cancer R&D. To learn more, listen to our free webinar about these opportunities.
Find out about more than $7 Billion In Funding Opportunities for Cancer Research – and our webinar all about them
Dr. William Bozza discusses non-dilutive funding opportunities at NCI and NIH.
SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of US-based small businesses as well as collaborations with Academics.
SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, devices, etc.
In this webinar, we discuss process for applying, guidelines, key success components and insight into increasing chances for award.
Dr. Todd Haim of the National Cancer Institute SBIR Development Center describes the NCI’s SBIR and STTR programs, their structure, the Institute’s funding interests, and FAQs.
Dr. Meg Mooney of the National Cancer Institute discusses new initiatives to accelerate development of cancer therapies in the era of precision medicine.
Website Links
Address
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109